Drug Trial Radar · NCT07738614
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.
Conditions
- Obesity
- Overweight
Interventions
EloralintideDrug
Administered SC
PlaceboDrug
Administered SC
AcetaminophenDrug
Administered Oral Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acetaminophen Area Under the Concentration Versus Time Curve (AUC)Time frame: Baseline to Day 65
- Acetaminophen Maximum Observed Concentration (Cₘₐₓ)Time frame: Baseline to Day 65
- Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ)Time frame: Baseline to Day 65
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
ICON Early Phase Services
San Antonio, Texas
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.